74 related articles for article (PubMed ID: 11489756)
1. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention.
Brewer M; Utzinger U; Satterfield W; Hill L; Gershenson D; Bast R; Wharton JT; Richards-Kortum R; Follen M
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):889-93. PubMed ID: 11489756
[TBL] [Abstract][Full Text] [Related]
2. Rhesus macaque model for ovarian cancer chemoprevention.
Brewer M; Baze W; Hill L; Utzinger U; Wharton JT; Follen M; Khan-Dawood F; Satterfield W
Comp Med; 2001 Oct; 51(5):424-9. PubMed ID: 11924802
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents.
Brewer M; Utzinger U; Li Y; Atkinson EN; Satterfield W; Auersperg N; Richards-Kortum R; Follen M; Bast R
J Biomed Opt; 2002 Jan; 7(1):20-6. PubMed ID: 11818008
[TBL] [Abstract][Full Text] [Related]
4. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
Brewer M; Wharton JT; Wang J; McWatters A; Auersperg N; Gershenson D; Bast R; Zou C
Gynecol Oncol; 2005 Aug; 98(2):182-92. PubMed ID: 15907982
[TBL] [Abstract][Full Text] [Related]
5. Endogenous fluorescence spectroscopy of cell suspensions for chemopreventive drug monitoring.
Kirkpatrick ND; Zou C; Brewer MA; Brands WR; Drezek RA; Utzinger U
Photochem Photobiol; 2005; 81(1):125-34. PubMed ID: 15535738
[TBL] [Abstract][Full Text] [Related]
6. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer.
Brewer M; Ranger-Moore J; Satterfield W; Hao Z; Wang J; Brewer E; Wharton JT; Bast R; Zou C
Front Biosci; 2007 Jan; 12():2260-8. PubMed ID: 17127462
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
8. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.
Appierto V; Tiberio P; Villani MG; Cavadini E; Formelli F
Carcinogenesis; 2009 May; 30(5):824-31. PubMed ID: 19325135
[TBL] [Abstract][Full Text] [Related]
9. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
[TBL] [Abstract][Full Text] [Related]
11. Autofluorescence characterization for the early diagnosis of neoplastic changes in DMBA/TPA-induced mouse skin carcinogenesis.
Diagaradjane P; Yaseen MA; Yu J; Wong MS; Anvari B
Lasers Surg Med; 2005 Dec; 37(5):382-95. PubMed ID: 16240416
[TBL] [Abstract][Full Text] [Related]
12. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the autofluorescence of polymorphonuclear leukocytes, mononuclear leukocytes and cervical epithelial cancer cells for improved spectroscopic discrimination of inflammation from dysplasia.
Heintzelman DL; Lotan R; Richards-Kortum RR
Photochem Photobiol; 2000 Mar; 71(3):327-32. PubMed ID: 10732451
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Rac in fenretinide-induced apoptosis.
Kadara H; Tahara E; Kim HJ; Lotan D; Myers J; Lotan R
Cancer Res; 2008 Jun; 68(11):4416-23. PubMed ID: 18519704
[TBL] [Abstract][Full Text] [Related]
15. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
[TBL] [Abstract][Full Text] [Related]
16. Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer.
Zhu G; Cao X; Chang JY; Milas L; Wallace S; Li C
Oncol Rep; 2007 Sep; 18(3):645-51. PubMed ID: 17671714
[TBL] [Abstract][Full Text] [Related]
17. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
18. Increased level of the p67phox subunit of NADPH oxidase by 4HPR in head and neck squamous carcinoma cells.
Kim HJ; Oridate N; Lotan R
Int J Oncol; 2005 Sep; 27(3):787-90. PubMed ID: 16077929
[TBL] [Abstract][Full Text] [Related]
19. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
20. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
